This week it is quite likely that the Enzolytics (OTCMKTS:ENZC) stock is going to come on to the radars of many investors and that may be because of the announcement from the company this morning. The company is mainly focused on the development and advancement of its therapeutic products and also its research and development efforts.
On Tuesday, ENZC stock moved down 11.60% to $0.0415 with more than 4.8 million shares, compared to volume of 6.05 million shares. The stock moved within a range of $0.0404 – 0.0472 after opening trade at $0.0470.
Enzolytics, Inc. Announces U.S. Distribution of IPF Immune(TM) and Progress in each of its Therapeutic Platforms
This morning the company announced that the coming year could prove to be a transformative one for Enzolytics since it had devised plans for the purpose of advancing its three therapeutics platforms which are synergistic. The plan is expected to lead to the development of a range of clinical products for both veterinary and human use.
On the other hand, it was also announced that the dietary supplement from Enzolytics, IPF Immune therapeutics, which is meant for the self-defense system of the body had become available in the United States.
The product is going to be available to consumers through a range of national level retailers as well as through online channels. It was also noted that the demand for the product was steady and in order to meet the demand, the company was working on boosting production.